

ASX ANNOUNCEMENT

23 November 2021

RESIGNATION OF CHAIR AND NON-EXECUTIVE DIRECTOR

EZZ Life Science Holdings Limited (ASX: **EZZ** or the **Company**) advises that due to other commitments, Ms Philippa Lewis has resigned from her position as Chair and Non-Executive Director of the Company with immediate effect.

Ms Lewis has served as Chair and Non-Executive Director of the Company since 27 October 2020 and has contributed significantly to the success of the Company.

The Board sincerely thanks Ms Lewis for her outstanding dedication and contributions to the Company over the past year and wishes her all the very best for her future endeavours.

Ms Lewis said: *“It has been a privilege to chair the Board and work with senior management of the Company and I wish everyone at EZZ every success.”*

The Board is currently in discussions with suitable candidates for the role of Chair and Non-Executive Director and will update the market accordingly.

Resolution 2 (Item3) contained in the Notice of Annual General Meeting sent to shareholders will be withdrawn and will not be voted on at the Annual General Meeting scheduled for 30 November 2021.

This announcement has been authorised by the Board of EZZ Life Science Holdings Limited.

-ENDS-

For further information, please contact:

Investor Relations

www.ezzlife.com.au/investors

ir@ezzlife.com.au

About EZZ Life Science Holdings Limited

EZZ is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. EZZ is passionate about investing in the future of consumer health through the development of e-commerce and distribution of high-quality products via omnichannel models across Australia, New Zealand, China and worldwide.